Triple-negative breast cancer (TNBC) represents 15–20% of all breast cancers, which is characterized by the lack of hormone receptors (HR), including estrogen receptor (ER) and progesterone receptor (PR) expression, in addition to the lack of epidermal growth factor receptor-2 (HER-2) amplification [1]. Here, ESR1 is linked to triple-negative breast carcinoma.